Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Hexarelin

Examorelin, HEX

Quick Stats
Studies 233
Trials 61
Score 1
2000 pubmed

EP 60761 and EP 50885, two hexarelin analogues, induce penile erection in rats.

Melis. M R MR; Succu. S S; Spano. M S MS; Locatelli. V V; Torsello. A A; Muller. E E EE; Deghenghi. R R; Argiolas. A A

Key Findings

  • EP 60761 and EP 50885 trigger dose‑dependent penile erections in male rats when injected into the hypothalamus.
  • Effective doses are very low (20 ng for EP 60761, 1000 ng for EP 50885).
  • The erection effect is blocked by oxytocin‑receptor antagonists, nitric‑oxide synthase inhibition, N‑type calcium‑channel blockers, and morphine, indicating a central oxytocin/NO mechanism.

Practical Outcomes

  • These results are interesting for drug developers targeting sexual dysfunction, but they don’t provide a usable protocol for self‑experimentation. The required brain‑site delivery and animal‑only data mean there’s no safe, actionable way for enthusiasts to apply this now.

Summary

In rats, two hexarelin-like peptides (EP 60761 and EP 50885) caused spontaneous erections when they were injected directly into a brain region that controls sexual function. The effect depended on dose, was blocked by drugs that stop oxytocin signaling or nitric‑oxide production, and did not involve dopamine or NMDA pathways. However, the way the peptides were given (direct brain injection) makes the findings far from something you could try at home.

Abstract

The effect of hexarelin and four related peptide analogues, EP 40904, EP 40737, EP 50885 and EP 60761, injected into the paraventricular nucleus of the hypothalamus of male rats in doses between 2 and 2000 ng on spontaneous penile erection was studied. Of these peptides, EP 60761 and EP 50885, but not hexarelin, EP 40904 or EP 40737, increased dose-dependently the number of spontaneous penile erections. EP 60761 was active already at the dose of 20 ng, which induced the sexual response in 70% of the treated rats. The maximal response was induced by 200 ng of the peptide. EP 50885 was less potent than EP 60761, with 1000 ng being the minimal effective dose and 2000 ng as the dose required to induce the maximal response. At the doses used, both peptides also increased slightly the number of spontaneous yawning episodes. EP 60761- and EP 50885-induced penile erection was prevented by the oxytocin receptor antagonist [d(CH(2))(5)Tyr(Me)(2)-Orn(8)]vasotocin (0.1-1 microg) given intracerebroventricularly (i.c.v.), but not into the paraventricular nucleus (0.1-1 microg), by the competitive nitric oxide (NO) inhibitor N(G)-nitro-L-arginine methyl ester (L-NAME) given either into the paraventricular nucleus (10-20 microg) or i.c.v. (75-150 microg), by the N-type Ca(2+) channel blocker omega-conotoxin-GVIA (2-5 ng) or by the opiate morphine (1-10 microg), but not by the dopamine receptor antagonist (Z)-4-[3-[2-(trifluoromethyl)-9H-thioxanthen-9-ylidene]propyl]-1-p ipe razine-ethanol (cis-flupenthixol) (10 microg) or by the N-methyl-D-aspartic acid (NMDA) receptor antagonist (5R, 10S)-(+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5, 10-imine ((+)-MK-801) (1 microg), all given into the paraventricular nucleus before either peptide. The present results show that EP 60761 and EP 50885 induced penile erection by increasing central oxytocin transmission, possibly by activating NO synthase in the cell bodies of oxytocinergic neurons located in the paraventricular nucleus that control penile erection.

Study Information

Provider

pubmed

Year

2000

Date

2000-09-15T00:00:00.000Z

DOI

10.1016/s0014-2999(00)00481-7